Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Victoria Mateos

Showing results (11-20 of 231) with videos related to

Pageof 24
Sort By:
Blood Reviews|April 19, 2011
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?Antonio Palumbo, Maria-Victoria Mateos, Sara Bringhen, et al.
Hematology (Amsterdam, Netherlands)|April 18, 2012
Multiple myeloma: treatment evolutionJesus F San Miguel, Maria Victoria Mateos, Enrique Ocio, et al.
The Lancet. Haematology|July 21, 2024
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategiesNiels W C J van de Donk, Ajai Chari, Maria Victoria Mateos
Expert Opinion on Biological Therapy|August 18, 2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myelomaSagar Lonial, Jonathan Kaufman, Donna Reece, et al.
Blood Reviews|April 17, 2021
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment optionsKarthik Ramasamy, Francesca Gay, Katja Weisel, et al.
Hematology/Oncology Clinics of North America|September 13, 2014
Monoclonal gammopathy of undetermined significance and smoldering multiple myelomaRobert A Kyle, Jesus F San-Miguel, Maria-Victoria Mateos, et al.
Current Medical Research and Opinion|June 15, 2007
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemiaDusan Kotasek, Jean-Luc Canon, Maria Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 27, 2012
Acute loss of vision as the initial symptom of multiple myelomaFernando Javier Vázquez, Natalia Sobenko, Natalia Schutz, et al.
Journal of Cellular and Molecular Medicine|March 7, 2020
FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myelomaAna Belén Herrero, Dalia Quwaider, Luis Antonio Corchete, et al.
Drug Design, Development and Therapy|February 9, 2017
Plitidepsin: design, development, and potential place in therapySara Alonso-Álvarez, Emilia Pardal, Diego Sánchez-Nieto, et al.
Pageof 24

Showing results (11-20 of 231) with videos related to

Sort By:
Pageof 24
Blood Reviews|April 19, 2011
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?Antonio Palumbo, Maria-Victoria Mateos, Sara Bringhen, et al.
Hematology (Amsterdam, Netherlands)|April 18, 2012
Multiple myeloma: treatment evolutionJesus F San Miguel, Maria Victoria Mateos, Enrique Ocio, et al.
The Lancet. Haematology|July 21, 2024
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategiesNiels W C J van de Donk, Ajai Chari, Maria Victoria Mateos
Expert Opinion on Biological Therapy|August 18, 2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myelomaSagar Lonial, Jonathan Kaufman, Donna Reece, et al.
Blood Reviews|April 17, 2021
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment optionsKarthik Ramasamy, Francesca Gay, Katja Weisel, et al.
Hematology/Oncology Clinics of North America|September 13, 2014
Monoclonal gammopathy of undetermined significance and smoldering multiple myelomaRobert A Kyle, Jesus F San-Miguel, Maria-Victoria Mateos, et al.
Current Medical Research and Opinion|June 15, 2007
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemiaDusan Kotasek, Jean-Luc Canon, Maria Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 27, 2012
Acute loss of vision as the initial symptom of multiple myelomaFernando Javier Vázquez, Natalia Sobenko, Natalia Schutz, et al.
Journal of Cellular and Molecular Medicine|March 7, 2020
FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myelomaAna Belén Herrero, Dalia Quwaider, Luis Antonio Corchete, et al.
Drug Design, Development and Therapy|February 9, 2017
Plitidepsin: design, development, and potential place in therapySara Alonso-Álvarez, Emilia Pardal, Diego Sánchez-Nieto, et al.
Pageof 24